Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada

Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and immune eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Jenna Shaw, Mahmoud Elsawy, Rachel Nielsen, Amye Michelle Harrigan, Tara T. DiCostanzo, Laura V. Minard
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Current Oncology
Subjects:
CAR T-cell therapy
axicabtagene ciloleucel
large B-cell lymphoma
guideline adherence
guideline utilization
toxicity management
Online Access:https://www.mdpi.com/1718-7729/32/1/2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items